Drug facts
MoleculeNintedanib (Ofev)
Generics already compete: 9 makers on the market. 18 A-rated products from 9 makers substitute at the counter.
Ofev was first approved by the FDA on 10/15/2014 under NDA 205832; the application holder is Boehringer Ingelheim Pharmaceuticals Inc.
The latest NADAC for NINTEDANIB ESYLATE 150 MG CAP is $12.06 per unit (as of 10/28/2026).
Holder Boehringer Ingelheim Pharmaceuticals IncApplication NDA 205832Approved 10/15/2014
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
1,133days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved10/15/2014
Exclusivity ends03/06/2027
Last patent12/07/2029
201520182021202420272030
- Latest patent
- 12/07/2029Ofev Orange Book
- Exclusivity
- 03/06/2027Ofev Orange Book
02Competition
- Generics
- 9 generic makers Orange Book
- Staged generics
- 4 passed FDA review, awaiting market entry FDA
- First generic approved
- 04/02/2026 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Nintedanib profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $12.06 per unitNINTEDANIB ESYLATE 150 MG CAP, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Boehringer Ingelheim Pharmaceuticals Inc Orange Book
- Application
- NDA 205832 Orange Book
- First approved
- 10/15/2014 Orange Book
- Dosage forms
- capsule
- Routes
- oral
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.